Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure.
Hypoxanthine arabinoside pharmacokinetics were measured during an adenine arabinoside continuous intravenous infusion and during hemodialysis in a patient with renal failure. Therapeutic guidelines for adenine arabinoside in renal failure are provided based on an elimination half-life of 4.7 h and a plasma clearance of 87.9 ml/min for the hypoxanthine metabolite.
D058186:Acute Kidney Injury / Q000378:metabolism*; D000293:Adolescent; D001087:Arabinonucleosides / Q000097:blood / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006561:Herpes Simplex / Q000188:drug therapy; D006801:Humans; D007042:Hypoxanthines / Q000097:blood / Q000378:metabolism*; D007263:Infusions, Parenteral; D007700:Kinetics; D008657:Metabolic Clearance Rate; D006435:Renal Dialysis; D014740:Vidarabine / Q000378:metabolism* / Q000627:therapeutic use
D001087:Arabinonucleosides; D007042:Hypoxanthines; C008099:hypoxanthine arabinoside; D014740:Vidarabine